DelveInsight’s, “Hemophilia A Pipeline Insights 2026” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia A pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hemophilia A Pipeline @ https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020

Key Takeaways from the Hemophilia A Pipeline Report

• On June 15, 2026- Bayer conducted a phase 1/2 study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own.
• On June 12, 2026- Novo Nordisk A/S initiated a study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study.
• On June 12, 2026- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. announced a phase III study is a single arm, open, multicenter clinical trial in which the previous treated severe hemophilia A patients receive recombinant human coagulation factor VIII for injection to evaluate the efficacy and safety of on-demand treatment in the event of new bleeding events. If evaluable surgical cases occur, the overall efficacy and safety of recombinant human coagulation factor VIII for injection as a replacement therapy for severe hemophilia A PTPs during the perioperative period will be evaluated.
• On June 08, 2026- Hoffmann-La Roche conducted a phase III study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without inhibitors. The study will include people aged ≥12 years old with severe or moderate congenital hemophilia A without inhibitors on previous FVIII prophylaxis treatment.
• DelveInsight’s Hemophilia A pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Hemophilia A treatment.
• The leading Hemophilia A Companies such as Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, LLC, CSL Behring and others.
• Promising Hemophilia A Pipeline Therapies such as Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.

Stay ahead with the most recent Hemophilia A pipeline outlook with DelveInsight @ Hemophilia A Treatment Drugs

The Hemophilia A Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hemophilia A Pipeline Report also highlights the unmet needs with respect to the Hemophilia A.

Hemophilia A Overview

Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. People with hemophilia A will bleed more than normal after an injury, surgery, or dental procedure. This disorder can be severe, moderate, or mild. In severe cases, heavy bleeding occurs after minor injury or even when there is no injury (spontaneous bleeding). Bleeding into the joints, muscles, brain, or organs can cause pain and other serious complications. In milder forms, there is no spontaneous bleeding, and the disorder might only be diagnosed after a surgery or serious injury. Hemophilia A is caused by having low levels of a protein called factor VIII. Factor VIII is needed to form blood clots. The disorder is inherited in an X-linked recessive manner and is caused by changes (mutations) in the F8 gene.

Hemophilia A Emerging Drugs Profile

• AGN-193408: Allergan

Allergan is conducting a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-group (Cohort 2) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension. It is an implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix.

• OCTA101: Octapharma

Octapharma is evaluating OCTA101 (a human-cl rhFVIII and recombinant human von Willebrand Factor fragment dimer) under a Phase 1/2 study, which will be a dose escalation study in adults in 5 cohorts, with the main purpose to assess the safety of subcutaneous injection of OCTA101 (in previously treated adult patients with severe hemophilia A. The study also aims to assess the pharmacokinetics (PK) characteristics, dose proportionality, and subcutaneous bioavailability of OCTA101 compared with intravenous administration of Nuwiq (Human-cl rh FVIII), in order to define the prophylactic treatment (dose and injection interval) that would result in protective trough levels of FVIII:C for future Phase 3 studies. By Data Monitoring Committee recommendation, patients enrolled in cohorts 1, 2 and 3 will proceed to 3-month prophylactic treatment to receive daily dosing of OCTA101 for 3 months.

• Valoctocogene roxaparvovec: BioMarin Pharmaceuticals

Valoctocogene roxaparvovec, is an investigational gene therapy in clinical trials for the treatment of Hemophilia A and has not been determined to be safe or effective. Valoctocogene roxaparvovec is administered as a single infusion. The ongoing clinical trials will determine if the new gene will enable the body to produce factor VIII. Following infusion, clinical trial subjects are being evaluated to determine the safety profile, changes in Factor VIII activity levels, changes in factor replacement usage, changes in reported bleeds requiring factor replacement, and quality of life measures, among other endpoints.

The Hemophilia A Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia A with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.
• Hemophilia A Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hemophilia A Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia A market

Explore groundbreaking therapies and clinical trials in the Hemophilia A Pipeline @ New Hemophilia A Drugs

Hemophilia A Companies

Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, LLC, CSL Behring and others.

Hemophilia A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Hemophilia A Products have been categorized under various Molecule types such as

• Small molecules
• Gene Therapies
• Bispecific antibodies
• Recombinant proteins
• Fusion Proteins
• Coagulants
• Blood coagulation factor replacements

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hemophilia A Market Drivers and Barriers

Scope of the Hemophilia A Pipeline Report

• Coverage- Global
• Hemophilia A Companies- Hoffmann-La Roche, Chugai Pharmaceutical, Shire, Pfizer, BioMarin Pharmaceutical, Sinocelltech Ltd., Bayer, Ultragenyx Pharmaceutical, Spark Therapeutics, Octapharma, ApcinteX Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, LLC, CSL Behring and others.
• Hemophilia A Pipeline Therapies- Emicizumab, rFVIIa, aPCC, BAX 888, OBIZUR, BIIB031 (rFVIIIFc), Recombinant Human Coagulation FVIII, and others.
• Hemophilia A Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hemophilia A Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hemophilia A Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hemophilia A Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Hemophilia A: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hemophilia A – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Hemophilia A Collaboration Deals
9. Late Stage Products (Pre-registration)
10. Valoctocogene roxaparvovec: BioMarin Pharmaceutical
11. Late Stage Products (Phase III)
12. Giroctocogene fitelparvovec: Pfizer/ Sangamo Therapeutics
13. Mid Stage Products (Phase II)
14. Comparative Analysis
15. NNC0365-3769 A (Mim8): Novo Nordisk A/S
16. Early Stage Products (Phase I/II)
17. Comparative Analysis
18. BAX 888: Baxalta / Shire
19. BAY2599023: Bayer / Ultragenix Pharmaceutical
20. Early Stage Products (Phase I)
21. Gene therapy: Expression Therapeutics, LLC
22. Hemophilia A Key Companies
23. Hemophilia A Key Products
24. Hemophilia A- Unmet Needs
25. Hemophilia A- Market Drivers and Barriers
26. Hemophilia A- Future Perspectives and Conclusion
27. Hemophilia A Analyst Views
28. Hemophilia A Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hemophilia-a-pipeline-insight-2020